Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LakeShore Biopharma ( (LSB) ) has provided an announcement.
On August 28, 2025, LakeShore Biopharma announced the receipt of a revised preliminary non-binding proposal from a consortium led by Oceanpine Capital to acquire all outstanding ordinary shares not owned by the consortium. The proposal, which maintains the original offer price of US$0.86 per share, led to the formation of a special committee to evaluate the offer. The consortium, owning 52.1% of the company’s shares, has agreed to support the transaction, but the board has yet to make a decision, leaving the outcome uncertain.
The most recent analyst rating on (LSB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSB Stock Forecast page.
Spark’s Take on LSB Stock
According to Spark, TipRanks’ AI Analyst, LSB is a Neutral.
The overall stock score is primarily influenced by the company’s financial performance challenges, including persistent losses and negative cash flows. Technical analysis indicates a bearish trend, further impacting the score. The lack of valuation metrics such as P/E ratio and dividend yield also contributes to the low score.
To see Spark’s full report on LSB stock, click here.
More about LakeShore Biopharma
LakeShore Biopharma is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer. The company operates in China, Singapore, and the Philippines, and utilizes its proprietary PIKA® immunomodulating technology platform to target various virus infections.
Average Trading Volume: 303,640
Technical Sentiment Signal: Sell
Current Market Cap: $33.5M
See more data about LSB stock on TipRanks’ Stock Analysis page.